• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降压药物的抗蛋白尿作用:非糖尿病患者与糖尿病患者之间的差异。

The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.

作者信息

de Jong P E, Heeg J E, Apperloo A J, de Zeeuw D

机构信息

Department of Medicine, State University Hospital, Groningen, The Netherlands.

出版信息

J Cardiovasc Pharmacol. 1992;19 Suppl 6:S28-32. doi: 10.1097/00005344-199219006-00006.

DOI:10.1097/00005344-199219006-00006
PMID:1382162
Abstract

The mechanism of the antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors in diabetic and nondiabetic renal disease is as yet unknown. A meta-analysis of studies on the effects of ACE inhibitors and other antihypertensive drugs on proteinuria, blood pressure, and renal hemodynamics in nondiabetic renal disease revealed that ACE inhibitors lower proteinuria more than other antihypertensives. Moreover, a close correlation (p less than 0.01) between changes in urinary protein loss and in filtration fraction was found, whereas such a correlation could not be detected between changes in proteinuria and in blood pressure. This suggests that, at least in nondiabetic renal disease, the fall in proteinuria during ACE inhibition is the consequence of the intrarenal effect of the drug more than the systemic effect. Data on the mechanism of action of ACE inhibitors in diabetic microalbuminuria and in diabetic overt proteinuria are less consistent. A fall in proteinuria on antihypertensive drugs in these patients can be observed also without a significant fall in blood pressure, and without any change in filtration fraction. We therefore conclude that one should be cautious in extrapolating the data from studies in diabetic renal disease to patients with nondiabetic nephropathies. Moreover, we argue also that nonhemodynamic effects of ACE inhibitors also could be involved in the antiproteinuric effect of these drugs.

摘要

血管紧张素转换酶(ACE)抑制剂在糖尿病和非糖尿病肾病中发挥抗蛋白尿作用的机制尚不清楚。一项关于ACE抑制剂和其他降压药物对非糖尿病肾病患者蛋白尿、血压及肾血流动力学影响的研究的荟萃分析显示,ACE抑制剂降低蛋白尿的效果优于其他降压药。此外,研究发现尿蛋白丢失的变化与滤过分数的变化之间存在密切相关性(p<0.01),而蛋白尿变化与血压变化之间未检测到这种相关性。这表明,至少在非糖尿病肾病中,ACE抑制期间蛋白尿的下降是药物肾内作用的结果,而非全身作用。关于ACE抑制剂在糖尿病微量白蛋白尿和糖尿病显性蛋白尿中的作用机制的数据不太一致。在这些患者中,使用降压药物后蛋白尿下降,而血压无显著下降,滤过分数也无任何变化。因此,我们得出结论,将糖尿病肾病研究的数据外推至非糖尿病肾病患者时应谨慎。此外,我们还认为,ACE抑制剂的非血流动力学效应也可能参与了这些药物的抗蛋白尿作用。

相似文献

1
The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.降压药物的抗蛋白尿作用:非糖尿病患者与糖尿病患者之间的差异。
J Cardiovasc Pharmacol. 1992;19 Suppl 6:S28-32. doi: 10.1097/00005344-199219006-00006.
2
Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.
Nephrol Dial Transplant. 1995 Nov;10(11):1963-74.
3
Renal protection and antihypertensive drugs: current status.肾脏保护与抗高血压药物:现状
Drugs. 1999 May;57(5):665-93. doi: 10.2165/00003495-199957050-00002.
4
Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?糖尿病和非糖尿病慢性肾脏病中通过阻断肾素-血管紧张素-醛固酮系统实现的肾脏保护作用。肾内血管紧张素转换酶活性在治疗抵抗中的具体作用?
Minerva Med. 2004 Oct;95(5):395-409.
5
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.患者因素在非糖尿病和糖尿病肾病抗蛋白尿干预治疗抵抗中的作用
Kidney Int Suppl. 2000 Apr;75:S32-7.
6
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).雷米普利对蛋白尿性非糖尿病肾病患者肾小球滤过率下降及终末期肾衰竭风险影响的随机安慰剂对照试验。意大利肾脏病流行病学研究组(GISEN组)
Lancet. 1997 Jun 28;349(9069):1857-63.
7
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].[血管紧张素转换酶抑制剂对慢性肾衰竭进展的影响]
Presse Med. 2002 Nov 9;31(36):1714-20.
8
Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.I型和II型糖尿病微量白蛋白尿患者的肾脏保护与血管紧张素转换酶抑制作用
J Hypertens Suppl. 1996 Dec;14(6):S11-4.
9
Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.维拉帕米与群多普利治疗非糖尿病肾病的抗蛋白尿疗效比较
Nephrol Dial Transplant. 1999 Jan;14(1):98-104. doi: 10.1093/ndt/14.1.98.
10
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.血管紧张素转换酶抑制剂与进行性肾功能不全。当前经验与未来方向。
Ann Intern Med. 1989 Sep 15;111(6):503-16. doi: 10.7326/0003-4819-111-6-503.

引用本文的文献

1
ACE inhibitors and the kidney. A risk-benefit assessment.血管紧张素转换酶抑制剂与肾脏。风险效益评估。
Drug Saf. 1996 Sep;15(3):200-11. doi: 10.2165/00002018-199615030-00005.